January 23, 2013 — The Radiological Society of North America (RSNA) Meeting, held annually in Chicago, Ill., is one of the largest and most prestigious medical imaging conferences in the world. Top researchers often choose this venue to announce significant results from their clinical work. One of the most exciting areas of modern medicine discussed at last year's meeting was molecular imaging. Many attendees expressed interest towards a full session dedicated to this new form of imaging entitled, "Breast Imaging in the Era of Molecular Medicine."

Molecular breast imaging (MBI), also commonly referred to as breast-specific gamma imaging (BSGI), was a key topic in the dedicated session with more than a third of the lectures examining its role in early breast cancer detection or patient management. MBI can detect breast cancer missed by mammography, according to clinical data presented by Rachel Brem from George Washington University Medical Center. In the work, 364 high-risk patients who had a recent, negative mammogram underwent an MBI examination. In this group, MBI detected breast cancer in nine patients. All cancers were in women with dense breasts.

According to Brem, director of Breast Imaging and vice chair of Radiology at George Washington, "We have long recognized that patients at high-risk for breast malignancy would likely benefit from additional imaging beyond the mammogram. These results indicate that MBI/BSGI could be a very good option for this population; we found breast cancer in 2.5 percent of theses patients who had a recent, negative mammogram. That's pretty impressive and these results are similar to those from the Mayo clinic." She continued, "Although breast MRI is another option, in our practice we find that many patients are unable to have an MRI such as those with pacemakers, claustrophobia, etc., and for others, the cost of an MRI study is simply out of reach. The MBI/BSGI procedure provides us with a low-cost, well tolerated exam that is clearly capable of filling the need for the high-risk group, especially for women who have dense breasts which can make reading the mammogram more difficult."

For more: www.molecularbreastimaging.com


Related Content

News | Radiopharmaceuticals and Tracers

Nov. 18, 2025 — Siemens Healthineers positron emission tomography (PET) radiopharmaceutical companies PETNET Solutions ...

Time November 18, 2025
arrow
News | Artificial Intelligence

Nov. 6, 2025 — Lunit, a provider of AI for cancer diagnostics and precision oncology, recently announced that Volpara ...

Time November 07, 2025
arrow
Feature | Breast Imaging

Despite decades of progress in breast imaging, one challenge continues to test even the most skilled radiologists ...

Time October 24, 2025
arrow
News | Radiology Imaging | UC San Diego Health

Oct. 16, 2025 — A strategic collaboration between UC San Diego Health and GE HealthCare will focus on bringing advanced ...

Time October 20, 2025
arrow
News | Radiopharmaceuticals and Tracers

Sept. 20, 2025 — A promising new PET tracer can visualize a protein that is commonly overexpressed in triple-negative ...

Time September 18, 2025
arrow
News | Radiopharmaceuticals and Tracers

Sept. 11, 2025 — A new PET tracer can provide insights into how spinal cord injuries affect not only the spinal cord ...

Time September 12, 2025
arrow
News | Focused Ultrasound Therapy

Aug. 26, 2025 — In a quest for ever-more-effective treatments for pancreatic cancer, HonorHealth Research Institute is ...

Time August 29, 2025
arrow
News | Artificial Intelligence

July 22, 2025 — GE HealthCare has topped a U.S. Food and Drug Administration (FDA) list of AI-enabled medical device ...

Time July 23, 2025
arrow
News | PET Imaging

May 30, 2025 — GE HealthCare recently announced that the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines) ...

Time May 30, 2025
arrow
News | Artificial Intelligence

March 10, 2025 — Lunit, a provider of AI-powered solutions for cancer diagnostics and therapeutics, has published a ...

Time March 10, 2025
arrow
Subscribe Now